Search results for " recombinant"

Article Top Process Development Trends for 2021 and a Look into 2022
mRNA therapies offer manufacturing advantages over recombinant proteins, and they are more cost-effective and faster to produce than most therapeutics, not to mention their flexibility. This infograph…

Article Maximum Output Starts with Optimized Upstream Processing
Significant growth in the development and manufacturing of biologics—from traditional recombinant proteins and monoclonal antibodies (mAbs) to advanced multispecifics, antibody-drug conjugates, viral …

Article Cell-free Expression Systems Pose Cell Culture Alternative
During a short period of time, the system can make protein biologics with high efficiency with minimal by-products, and you don’t have to worry about proteolytic of recombinant protein caused by prote…

Article Novavax Reports on Two Vaccine Efficacy Studies
Novavax announced on June 14, 2021, results from two studies of is recombinant nanoparticle protein-based COVID-19 vaccine; in a large study, the vaccine candidate demonstrated 90.4% efficacy overall …

Article Virus-like Particles as Therapeutic Moieties of the Future
These biophysical, biochemical, and immunochemical methods ensure process reproducibility and product consistency in recombinant VLPs during the manufacturing process. These characterization methods a…

Article Technology Innovations Improve Process Chromatography Performance
“New choices for Protein A, such as, for example, a new recombinant Protein A resin developed by Avantor, [can]addresses challenges of limited supply,” Deorkar continues. “The new resin is built on a …

Article Eliminating Residual Impurities Starts with a Strategic Plan
EDQM, EurPh, Products of Recombinant DNA Technology (0784) (Strasborg, France). 4. USP, USP General Chapter , “Residual Host Cell Protein Measurement in Biopharmaceuticals,” USP 39-NF 34 (Rockvil…

Article Biomanufacturing: Demand for Continuous Bioprocessing Increasing
Some commercial biopharmaceutical products that essentially require perfusion’s generally milder/less intense processing conditions, including Factor VIII (the largest recombinant molecule biopharmace…

Article Mapping a Route for Cell and Gene Therapy Process Development
On a big-picture level, the increased demand for viral-vector manufacturing services to support clinical trials for recombinant adeno-associated virus (rAAV)-based gene therapies has led to a shortage…

Article Why, Why, Why…ELISA? A Look at the Benchmark HCP Assay
Click here to read the article >> Biologics developers and manufacturers demand an accurate and reliable assay for host cell protein (HCP) quantitation. Let’s take a close look at why analytica…

Previous PageNext Page